摘要
目的:评价培美曲赛(PEM)联合顺铂一线治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法:将66例晚期NSCLC患者随机分为两组,采用培美曲赛500 mg/m2第1天+顺铂20 mg/m2第1～3天(治疗组)治疗33例和长春瑞滨25 mg/m2第1、8天+顺铂20mg/m2第1～3天(对照组)治疗33例,每3周重复,治疗2～6个疗程。按照RECIST标准和NCI-CTC标准分别评价疗效和毒性。结果:治疗组有效率为51.5%,对照组的有效率为41.2%,治疗组中位生存时间11.1个月,1年生存率39.4%,对照组分别为9.9个月,33.3%,两组比较均无统计学差异(P均>0.05);血液学毒性总发生率及Ⅲ～Ⅳ级发生率治疗组分别为42.4%、15.2%,对照组分别为75.9%、36.3%,两组比较均有统计学差异(P均<0.05)。结论:培美曲赛联合顺铂一线治疗晚期NSCLC疗效确切,其与长春瑞滨联合顺铂比较,血液学毒性反应低,适合于化疗耐受性较差的晚期NSCLC患者。
Objective：To evaluate Pemetrexed（PEM） plus Cisplatin first-line treatment of advanced non-small cell lung cancer（NSCLC） efficacy and safety.Methods：66 patients with advanced NSCLC patients were randomly divided into two groups,33 patients were received Pemetrexed 500 mg/m2 on day 1 and Cisplatin 20 mg/m2 on days 1 to 3 therapy（treatment group）.33 patients were received Vinorelbine 25 mg/m2 on day 1,8 and Cisplatinon 20 mg/m2 on days1 to 3（control group） therapy.According to RECIST standard and NCI CTC standard,therapeutic evaluation and toxicity respectively will be evaluated after 2～6 cycles.Results： Treatment group and control group for the effective laser is 51.5% and 41.2 %respectively,the treatment group median survival time was 11.1 months,1 year survival rate was 39.4%,the control group was 9.9 months,33.3% respectively.Two groups of comparisons had no statistically significant（P0.05）;The total and Ⅲ～Ⅳ level incidence rate of hematology toxicity,the treatment group is 42.4% and 15.2% respectively,the control group,75.9% and 36.3% respectively.The two groups of comparisons had statistically significant（P0.05）.Conclusions： Pemetrexed plus Cisplatin first-line treatment of advanced NSCLC definite effect with Vinorelbine plus Cisplatin compared low hematology toxicity,suitable for the poor chemotherapy tolerability patients with advanced NSCLC.
出处
《中国民康医学》
2011年第19期2372-2373,2378,共3页
Medical Journal of Chinese People’s Health
